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Background: Hepatitis B virus (HBV) vaccine antibody response has been associated with reduced risk of AIDS or
death. However, it is unknown whether HBV vaccine responsiveness is associated with improved immune
reconstitution during treatment with combination antiretroviral therapy (cART). We evaluated the relationship
between HBV vaccine response status and CD4 reconstitution on cART in the U.S Military HIV Natural History Study.
Methods: Participants with viral load <400 copies/mL within 1 year on initial cART and documented HBV
vaccination and surface antibody (anti-HBs) prior to cART were included. Participants were characterized as HBV
vaccine responders (anti-HBs ≥10 IU/L) or non-responders (<10 IU/L) and further divided into 2 groups based on
vaccine administration before or after HIV diagnosis. Linear mixed regression was used to model CD4 reconstitution
during the first year of cART.
Results: Of the 307 and 169 participants vaccinated before or after HIV diagnosis, HBV vaccine response occurred in
288 (94%) and 74 (44%), respectively. For those vaccinated before HIV diagnosis, CD4 counts increased by a median
190 [IQR 99–310] cells/mm3 for responders and 186 [IQR 116–366] cells/mm3 for non-responders during the first
year (P = 0.684). Participants vaccinated after HIV diagnosis had median increases of 185 [IQR 76–270] and 143 [IQR
47–238] cells/mm3 for responders and non-responders, respectively (P = 0.134). In contrast to those with CD4 > 350
cells/mm3 at cART initiation, participants with CD4 < 200 and 200–350 cells/mm3 had significantly reduced CD4
gains in both groups by longitudinal mixed models, but there was no difference in CD4 recovery according to HBV
vaccine seroresponse.
Conclusions: Although HBV vaccine responsiveness is associated with a reduction in HIV disease progression, HBV
vaccine responders do not achieve greater CD4 gains during the first year of cART. Additional clinical markers are
needed to predict the magnitude of post-cART immune recovery.
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In the setting of HIV infection, immunization with hepa-
titis B virus (HBV) vaccine is essential in order to prevent
liver-related morbidity and mortality than can occur with
HBV co-infection [1,2]. However, HIV-infected patients
have diminished vaccine responsiveness compared to
HIV-uninfected persons [3-6]. For example, positive seror-
esponses occur in 20-62% of persons vaccinated after HIV
diagnosis compared to approximately 90% in HIV-
uninfected individuals. The development of a positive
HBV vaccine antibody response involves not only T-cell
function but also other functional pathways including B-
cell activity and antigen presentation of the peptide-based
vaccine [7-9]. Since HBV vaccine seroresponse requires
preserved function in a number of immune pathways, the
evaluation of vaccine responsiveness in HIV-infected per-
sons may provide useful information about the immune
status of the individual beyond measurement of CD4 cell
counts.
In a previous study, we reported the risk of developing
clinical acquired immune deficiency syndrome (AIDS)
or death is 2-fold higher in HBV vaccine non-responders
compared to responders after adjusting for HIV disease-
related factors such as CD4 count, viral load (VL), and use
of combination antiretroviral therapy (cART) [10]. Al-
though HBV vaccine response can predict HIV disease
outcomes, it is unknown whether HBV vaccine responders
have improved immune recovery during cART. Identifying
predictors of CD4 reconstitution during cART is clinically
important since the rate of both AIDS and serious non-
AIDS events decrease at higher CD4 counts, even among
the subgroup of individuals with CD4 counts >500 cells/
mm3 [11,12]. We retrospectively evaluated the relationship
between HBV vaccine response status and post-cART
CD4 cell gains in the U.S. Military HIV Natural History
Study.
Methods
The U.S. Military HIV Natural History Study is comprised
of over 5700 military beneficiaries with HIV infection as
previously described [13]. Participants were ≥18 years of
age and provided informed, written consent. Individuals
without prior HBV infection who achieved VL suppression,
defined as <400 copies/mL within 1 year on their initial
cART regimen, and maintained VL suppression for >1 year
were included. Participants were divided into 2 groups
according to the whether all vaccine doses were re-
ceived prior to HIV diagnosis or in the interval between
HIV diagnosis and cART initiation. Individuals who re-
ceived HBV vaccine doses both before and after HIV
diagnosis were excluded as were individuals vaccinated
after cART initiation. Participants were then characterized
according to HBV vaccine response, with responders
and non-responders defined as having an antibody toHBV surface antigen (anti-HBs) ≥10 or <10 IU/L,
respectively ≥30 days after last vaccination. For those
vaccinated prior to HIV diagnosis, the first available
anti-HBs determination was used to assign participants
into responder or non-responder categories. This study
was approved by the Uniformed Services University of
the Health Sciences Institutional Review Board.
The primary outcome was CD4 cell recovery during the
first year of cART in HBV vaccine responders compared
to non-responders. Continuous variables were analyzed by
t-test for normally distributed variables and Wilcoxon
for non-normally distributed variables. Normality was
assessed using Shapiro-Wilks test. P-values for categorical
variables were calculated using chi-squared or Fisher’s
exact test when appropriate. To assess and quantify the ef-
fect of HBV vaccine response on CD4 reconstitution after
cART initiation, all available CD4 counts for participants
from cART initiation to one year post-cART were ana-
lyzed. To quantify the adjusted effect of vaccine response
on the rate of CD4 increase after cART, longitudinal
mixed models were performed which allowed use of all
CD4 values in the window of interest while accounting for
within participant CD4 association. The model adjusts for
race, gender, age at cART initiation, AIDS before cART,
and HBV vaccine response status at baseline as well as
CD4 at cART and vaccine response status on CD4 gains
after cART. Power to detect differences among variables
was enhanced by multiple CD4 count measurements con-
tributed per participant. Lastly, sensitivity analyses were
performed for several variables, including year of cART
initiation, and time from HIV diagnosis to cART initiation.
Additional variables were used to assess effect modifica-
tion post hoc, however none of these variables were
significant modifiers for the outcome of interest.
Results
A total of 307 participants met criteria for HBV vaccination
prior to HIV diagnosis, including 288 (94%) responders
and 19 (6%) non-responders (Table 1). Demographic
characteristics were similar between groups except the
responder group had a higher proportion of African
Americans. The median CD4 count at cART initiation
was 360 [IQR 270–448] cells/mm3 compared to 298
[IQR 234–394] cells/mm3 for responders versus non-
responders (P = 0.398), respectively and VL was similar
between groups. Participants vaccinated prior to HIV
diagnosis had a median of 4 (IQR 2–5) CD4 count deter-
minations during the first year on cART and a median of 3
(IQR 2–5) values were available for those vaccinated be-
tween HIV diagnosis and cART initiation. Regimens com-
monly included non-nucleoside reverse transcriptase
inhibitors (NNRTIs) in both groups, however the median
year of cART initiation was later for responders compared
to non-responders (2008 vs 2003; P = 0.051).
Table 1 Baseline characteristics for participants vaccinated before or after HIV diagnosis










Number, n 307 288 (94) 19 (6) – 169 74 (44) 95 (56) –
Age at HIV diagnosis (years) 29 (25-36) 29 (25-36) 34 (26-41) 0.170 28 (24-34) 27 (24-32) 29 (25-34) 0.349
Gender, Male 291 (95) 274 (95) 17 (89) 0.260 148 (94) 63 (85) 85 (89) 0.540
Ethnicity 0.085 0.142
Caucasian 116 (38) 104 (36) 12 (63) 70 (41) 28 (38) 42 (44)
African American 134 (44) 129 (45) 5 (26) 69 (41) 28 (38) 41 (43)
Hispanic/Other 57 (18) 55 (19) 2 (11) 30 (18) 18 (24) 12 (13)
Median CD4 Count (cells/mm3) at HIV diagnosis 436 (307-570) 438 (312-570) 372 (282-561) 0.335 526 (405-711) 543 (422-724) 517 (382-676) 0.129
Median VL at HIV diagnosis (log10 copies/mL) 4.5 (3.9-5.0) 4.5 (3.9-5.0) 4.7 (4.2-5.1) 0.853 4.2 (3.5-4.4) 4.2 (3.4-4.6) 4.2 (3.5-4.4) 0.888
Number of HBV vaccine doses 3 (2-3) 3 (1-3) 3 (3-3) 0.101 3 (1-3) 2 (1-3) 3 (2-3) 0.585
Median time from last vaccination to anti-HBs determination
(months)
18.1 (6.1-57) 26 (7.4-67) 6.8 (4.3-15) 0.222 5.2 (2.8-6.8) 5.5 (2.8-7.1) 4.9 (2.7-6.4) 0.340
Median CD4 Count at last HBV vaccination (cells/mm3) – – – – 489 (353-628) 481 (331-621) 510 (394-629) 0.669
Median VL at last HBV vaccination (log10 copies/mL) – – – – 4.1 (3.6-4.6) 4.1 (3.7-4.6) 4.1 (3.3-4.4) 0.274
Year of cART initiation 2008 (2003-2010) 2008 (2003-2010) 2003 (2000-2008) 0.051 1998 (1997-2006) 2004 (1997-2009) 1998 (1997- 2004) 0.001
Median time from HIV diagnosis to cART initiation (months) 7.8 (2.0-27.0) 8 (2.1-29.0) 2.1 (1.3-11.0) 0.273 57 (29-91) 51 (29-93) 59 (29-90) 0.603
Median CD4 Count (cells/mm3) at cART initiation 356 (270-445) 360 (270-448) 298 (234-394) 0.398 379 (249-473) 390 (277-492) 377 (215-460) 0.137
Median VL at cART initiation (log10 copies/mL) 4.5 (4.0-5.0) 4.5 (3.9-5.0) 4.4 (4.3-5.0) 0.619 4.4 (3.6-4.8) 4.4 (3.9-4.7) 4.4 (3.5-4.8) 0.864
Initial cART regimen 0.669 0.612
NNRTI 193 (63) 180 (62) 13 (68) 67 (40) 31 (42) 36 (38)
Boosted PI 34 (11) 31 (11) 3 (16) 18 (11) 5 (7) 13 (14)
Unboosted PI 52 (17) 49 (17) 3 (16) 67 (40) 29 (39) 38 (40)
Triple NRTI 26 (8) 26 (9) 0 (0) 7 (4) 4 (5) 5 (5)
Other 2 (1) 2 (1) 0 (0) 10 (6) 5 (7) 0 (0)
Hepatitis C diagnosis before cART initiation 9 (3) 9 (3) 0 (0) 1.000 8 (5) 3 (4) 5 (5) 1.000
HBV, hepatitis B virus; responder, antibody to HBV surface antigen (anti-HBs) ≥10 IU/L; non-responder, anti-HBs <10 IU/L; VL, viral load; cART, combination antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase
inhibitor; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
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to cART initiation (n = 169), 74 (44%) were responders and
95 (56%) were non-responders. Demographic and vaccine-
related characteristics were similar between groups, includ-
ing the number of vaccine doses, and CD4 and VL at the
time of last vaccination. At cART initiation, the median
CD4 count (390 [IQR 277–492] vs 377 [IQR 215–460]
cells/mm3; P = 0.137) and median VL (4.4 [IQR 3.9-4.7] vs
4.4 [IQR 3.5-4.8] log10 copies/mL; P = 0.864) were not dif-
ferent for responders compared to non-responders, re-
spectively. Responders initiated cART at a later median
calendar year compared to non-responders (2004 vs. 1998;
P = 0.001) and the majority of participants in both groups
received protease inhibitor (PI)-based regimens.
Among those vaccinated before HIV diagnosis, the me-
dian CD4 cell gains 1 year post-cART were similar for
HBV vaccine responders compared to non-responders
(190 [IQR 99–310] cells/mm3 vs. 186 [IQR 116–366] cells/
mm3; P = 0.684, respectively). For participants vaccinated
after HIV diagnosis, vaccine responders had greater CD4
gains (185 [IQR 76–270] cells/mm3) compared to non-
responders (143 [IQR 47–238] cells/mm3), however the
difference was not statistically significant (P = 0.134). Lon-
gitudinal mixed models for CD4 gains during the first year
of cART (Table 2) showed that CD4 count <200 cells/mm3
at cART initiation was associated with reduced CD4 gains
for those vaccinated before (−208 cells/mm3, 95% CI −283,
−134; P < 0.001) and after HIV diagnosis (−188 cells/mm3,
95% CI −295, −81; P < 0.001). A similar effect was also ob-
served for participants with pre-cART CD4 counts be-
tween 200–350 cells/mm3 for those vaccinated before or
after HIV diagnosis (−141 cells/mm3, 95% CI −189, −94;
P < 0.001 and −81 cells/mm3, −167, 5; P = 0.067, respect-
ively). HBV vaccine responder status was not associated
with greater CD4 recovery in those vaccinated either be-
fore (−18 cells/mm3, 95% CI −79, 42; P = 0.551) or after
HIV diagnosis (26 cells/mm3, 95% CI −55, 108; P = 0.528).
Discussion
In addition to the importance of HBV vaccine in the
prevention of HBV infection, positive vaccine response
has been associated with improved HIV prognosis. In a
previous study, we found that 22% of HBV vaccine
non-responders developed AIDS or death compared toTable 2 Modeled CD4 gains after cART initiation for participa
Median [IQR] Change in CD
Characteristic Vaccinated before
HIV diagnosis
CD4 <200 cells/mm3at cART initiation −208 [−283, −134]
CD4 200–350 cells/mm3 at cART initiation −141 [−189, −94]
HBV vaccine responder at cART initiation −18 [−79, 42]
cART, combination antiretroviral therapy; IQR, interquartile range; HBV, hepatitis B v
*Model adjusted for HBV vaccine response status, race, gender, age at cART initiatio5% of responders (P < 0.001) [10]. Based on these find-
ings, we studied whether the beneficial functional im-
mune aspects inherent in vaccine responders translated
to more robust immune responses after initiation of
VL-suppressive cART. Characteristics associated with
differential CD4 gains on cART in previous studies
were no different among our participant groups, in-
cluding age, regimen type, duration of HIV infection,
and pre-cART CD4 counts and VL [14-16]. In accordance
with prior studies in our cohort [13,17], we observed that
CD4 gains were blunted in those with lower CD4 cell
counts at cART initiation, particularly in those with CD4
counts <200 cells/mm3. However, the magnitude of CD4
gains was comparable for HBV vaccine responders com-
pared to non-responders regardless of whether partici-
pants were vaccinated before or after HIV diagnosis.
Although HBV vaccine seroresponse did not predict CD4
reconstitution after cART initiation, response status re-
mains an important tool as a reduction in AIDS or death
events was observed in vaccine responders independent of
CD4 cell count in our prior study, including those with
CD4 counts >500 cells/mm3.
The immunity represented by CD4 count may not be
fully indicative of immune functions that lead to the pro-
duction of anti-HBs antibodies at an effective titer. In
addition to our current study examining CD4 outcomes
by HBV vaccine seroresponse, studies of other HIV prog-
nostic markers demonstrated similar findings. For ex-
ample, delayed-type hypersensitivity (DTH) response to
recall antigens, an assessment of cell-mediated immunity,
has been associated with HIV disease progression [18,19].
However, pre-cART DTH responsiveness did not predict
CD4 gains during VL-suppressive cART [20]. Discordance
between CD4 count and HIV clinical outcomes was ob-
served in the SILCAAT and ESPIRIT studies [21]. In these
clinical trials, infusion of interleukin-2 (IL-2) in addition
to cART resulted in larger, sustained CD4 gains compared
to cART alone. However, the increase in CD4 count did
not translate to improved clinical outcomes as measured
by development of opportunistic infections or death, as
there was no difference in these outcomes in those treated
with cART plus IL-2 compared to cART alone. The obser-
vation of nearly identical CD4 gains for HBV vaccine re-
sponders and non-responders during the first year ofnts vaccinated before or after HIV diagnosis
4 Cell Count (cells/mm3) 1 Year After cART Initiation*
P value Vaccinated between HIV
diagnosis and cART Initiation
P value
<0.001 −188 [−295, −81] <0.001
<0.001 −81 [−167, 5] 0.067
0.551 26 [−55, 108] 0.528
irus; responder, antibody to HBV surface antigen ≥10 IU/L.
n, and AIDS before cART at baseline.
Allen et al. BMC Infectious Diseases  (2015) 15:203 Page 5 of 6cART in our current study may be explained by differing
pathways involved in CD4 reconstitution during cART
compared to those responsible for development of HBV
vaccine seroresponse.
The strengths of this study include a population with
early enrolment after HIV infection and free access to
care, as these can be confounders in other cohorts.
Based on the composition of our military cohort, our
findings may not be applicable to women or those with
a history of intravenous drug use or HCV co-infection.
The magnitude of anti-HBs titers were not examined as
quantitative titers were not routinely performed in clin-
ical practice. Other limitations include the retrospective
study design and non-randomized administration of
HBV vaccine either before or after HIV diagnosis. The
vaccine manufacturer and dose administered were not
recorded, however there are conflicting data regarding
the efficacy of high-dose HBV in HIV-infected persons
[22,23]. The decision to initiate cART was non-
randomized and at the discretion of individual providers
and patients. Although cART regimens were compared
by drug class, specific regimens could not be directly
compared due to sample size constraints.
Conclusions
We observed no difference in CD4 gains for HBV vac-
cine responders compared to non-responders by the
examination of CD4 gains at 1 year post-cART and by
longitudinal mixed modeling of all CD4 values during
the first year of therapy. This lack of effect was observed
in those vaccinated before or after HIV diagnosis. Since
HBV vaccine responsiveness has been associated with
reduced risk of AIDS or death, it is possible that vaccine
responders may have improved immune recovery during
cART that is not measured by CD4 counts. For example,
T-cell activation and exhaustion, which have both been as-
sociated with HIV disease progression and death, may con-
tinue to have detrimental effects during VL-suppressive
cART [24,25]. The development and validation of other
clinically relevant immune correlates are necessary to bet-
ter predict both HIV progression and immune recovery
during cART.
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